NYSE:HYH - Halyard Health Stock Price, Price Target & More

Halyard Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HYH."

Halyard Health (NYSE:HYH) issued its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.59. The medical instruments supplier had revenue of $156.40 million for the quarter, compared to analysts' expectations of $155.08 million. Halyard Health had a net margin of 7.72% and a return on equity of 7.90%. The business's revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the business earned $0.48 earnings per share. View Halyard Health's Earnings History.

Halyard Health updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $1.65-$1.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.26.

5 Wall Street analysts have issued 1-year price objectives for Halyard Health's stock. Their predictions range from $50.00 to $67.00. On average, they anticipate Halyard Health's share price to reach $59.25 in the next year. This suggests a possible upside of 3.5% from the stock's current price. View Analyst Ratings for Halyard Health.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halyard Health in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Halyard Health include WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), CONSORT Med PLC/S (CSRMY), Invacare (IVC), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN) and NanoVibronix (NAOV).

News articles about HYH stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Halyard Health earned a media sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 47.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Halyard Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Channing Capital Management LLC (2.38%), Fox Run Management L.L.C. (0.03%) and McQueen Ball & Associates Inc. (0.01%). View Institutional Ownership Trends for Halyard Health.

HYH stock was sold by a variety of institutional investors in the last quarter, including Channing Capital Management LLC. View Insider Buying and Selling for Halyard Health.

HYH stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and McQueen Ball & Associates Inc.. View Insider Buying and Selling for Halyard Health.

Shares of HYH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HYH stock can currently be purchased for approximately $57.25.

Halyard Health has a market capitalization of $2.69 billion and generates $611.60 million in revenue each year. The medical instruments supplier earns $79.30 million in net income (profit) each year or $2.35 on an earnings per share basis. Halyard Health employs 13,000 workers across the globe.

Halyard Health's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The medical instruments supplier can be reached via phone at 678-425-9273 or via email at [email protected]